心臟中風診斷市場規模、佔有率和成長分析：按測試類型、平台、最終用戶、通路和地區分類－2026-2033年產業預測

2024 年全球心肌梗塞診斷市場價值為 45.2 億美元，預計到 2025 年將成長至 47.8 億美元，到 2033 年將成長至 75.2 億美元，在預測期（2026-2033 年）內複合年成長率為 5.82%。

全球心肌梗塞 (MYO) 診斷市場正日益受到先進技術和服務的驅動，這些技術和服務旨在快速檢測 MYO，例如高靈敏度肌鈣蛋白檢測以及心臟磁振造影 (MRI) 和電腦斷層掃描 (CT) 等影像平台。由於快速診斷能夠顯著降低死亡率，醫院和急診室正積極投資這些解決方案。將即時檢測 (PoC) 平台整合到數位健康生態系統中，有助於加快決策速度並縮短住院時間。隨著急診室對快速分流的需求不斷成長，製造商正在將無線連接和人工智慧 (AI) 功能整合到手持設備中。此外，當地診所正在使用攜帶式試劑盒與心臟科醫生即時聯繫，從而實現當日治療。向互通軟體、新型生物標記和分析技術的轉變進一步縮短了治療時間，而人工智慧則正在加速早期檢測，提高診斷工作流程的可靠性並增強市場信心。

全球心肌梗塞診斷市場按檢測類型、平台、最終用戶、分銷管道和地區進行細分。依檢測類型分類，可分為肌鈣蛋白（cTnI 和 cTnT）檢測、CK-MB（肌酸激酶-MB）檢測、肌紅蛋白檢測、BNP/NT-proBNP 檢測和心電圖 (ECG) 診斷。依平台分類，可分為高靈敏度檢測、標準檢測和即時檢測 (POC)。按最終用戶分類，可分為醫院急診室、重症監護室 (ICU) 和心臟監護病房以及門診診所。按分銷管道分類，可分為直銷和診斷設備分銷商。按地區分類，市場分析涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

全球心肌梗塞診斷市場成長要素

人們對心肌梗塞症狀的認知不斷提高，以及對快速診斷的迫切需求，顯著推動了對先進診斷工具的需求。隨著患者和看護者知識的不斷豐富，對更快、更準確的檢測方法的需求日益成長，迫使醫療機構在資源有限的情況下採用創新技術。這種意識的提高也推動了預防性篩檢措施的實施，使市場不再局限於緊急情況。因此，製造商看到了產品應用率的提高，從而增加了研發投入。這種活力正在形成一個持續成長的良性循環，而預防性健康管理的整體趨勢進一步加速了這個過程。

全球心肌梗塞診斷市場面臨的限制因素

對許多醫療機構，尤其是資源有限的機構而言，購買先進診斷設備需要大量資金投入，這構成了一項重大的財務挑戰。採用最尖端科技的高成本阻礙了小規模醫院和診所採用這些創新技術，迫使它們依賴較為陳舊、準確性較低的診斷方法。此外，預算限制也阻礙了現有系統的維護和升級，延長了採用週期。因此，市場滲透率仍不均衡，整體成長受到經濟因素的限制。財務壓力往往迫使醫療機構將重點放在眼前的臨床需求上，而不是優先考慮提升長期診斷能力這一更根本的挑戰。

全球心肌梗塞診斷市場趨勢

隨著複雜演算法日益整合到心臟影像影像系統中，全球心肌梗塞診斷市場正經歷著向人工智慧成像的重大轉變。這項創新實現了對心電圖 (ECG)、心臟超音波圖和電腦斷層掃描的即時分析，顯著縮短了讀取時間，並透過最大限度地減少檢查者之間的差異，提高診斷的可靠性。醫院正積極採用人工智慧平台來簡化工作流程，並增強臨床醫生對診斷的信心。供應商和科技公司之間的合作也日益普遍，使得將複雜的學習模型整合到診斷工具中變得更加容易。因此，這些進步加快了臨床決策速度，符合以價值為導向的醫療模式，最終使患者和醫療保健系統都受益。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球心臟病發作診斷市場規模：按檢測類型分類

• 肌鈣蛋白（cTnI、cTnT）檢測
• CK-MB（肌酸激酶-MB）
• 肌紅蛋白檢測
• BNP／NT-proBNP
• 心電圖（ECG）

全球心臟病發作診斷市場規模：按平台分類

• 高靈敏度檢測
• 標準檢測
• 即時檢測

全球心臟病發作診斷市場規模：按最終用戶分類

• 醫院急診室
• 重症監護室和心臟護理
• 門診部

全球心臟病診斷市場規模：按分銷管道分類

• 直銷
• 測試設備經銷商

全球心臟病診斷市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Abbott Laboratories（STAT Troponin）
• Roche Diagnostics（Elecsys Troponin T）
• Siemens Healthineers
• Beckman Coulter（Danaher）
• Ortho Clinical Diagnostics
• bioMerieux SA
• Quidel Corporation
• Response Biomedical
• Critical Diagnostics
• Randox Laboratories
• Tosoh Corporation
• Minicare（Philips）
• Radiometer Medical
• OPTI Medical Systems
• Microvix
• GenMark Diagnostics（Roche）
• Akers Biosciences
• Meso Scale Diagnostics
• Boditech Med Inc.
• BTNX Inc.

結論與建議

Global Heart Attack Diagnostics Market size was valued at USD 4.52 Billion in 2024 and is poised to grow from USD 4.78 Billion in 2025 to USD 7.52 Billion by 2033, growing at a CAGR of 5.82% during the forecast period (2026-2033).

The global heart attack diagnostics market is increasingly driven by advanced technologies and services aimed at the rapid detection of myocardial infarction, such as high-sensitivity troponin assays and imaging platforms like cardiac MRI and CT. Prompt diagnosis significantly reduces mortality rates, encouraging hospitals and emergency services to invest in these solutions. The integration of point-of-care platforms within digital health ecosystems facilitates swift decision-making and reduces hospital stays. With the demand for rapid triage in emergency departments, manufacturers are incorporating wireless connectivity and AI into handheld devices. Additionally, rural clinics are leveraging portable kits for instant cardiologist communication, enhancing same-day treatment. The shift towards interoperable software, emerging biomarkers, and analytics further accelerates time-to-therapy, while AI enhances early detection, boosting diagnostic workflow reliability and market confidence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Heart Attack Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Heart Attack Diagnostics Market Segments Analysis

The global heart attack diagnostics market is segmented based on test type, platform, end-user, distribution channel, and region. By test type, the market is categorized into Troponin (cTnI and cTnT) Tests, CK-MB (Creatine Kinase-MB) Tests, Myoglobin Tests, BNP/NT-proBNP Tests, and ECG Diagnostics. Based on platform, the market is divided into High-Sensitivity Assays, Standard Assays, and Point-of-Care (POC) Tests. By end-user, the market is segmented into Hospital Emergency Departments, ICUs & Cardiac Care Units, and Ambulatory Clinics. Based on distribution channel, the market is classified into Direct Sales and Laboratory Distributors. Geographically, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Heart Attack Diagnostics Market

The increasing awareness of heart attack symptoms and the critical need for prompt diagnosis significantly fuels the demand for advanced diagnostic tools. With patients and caregivers becoming more knowledgeable, there is a rising pursuit for quicker and more accurate testing options, which compels healthcare providers to embrace innovative technologies despite limited resources. This heightened awareness also encourages the implementation of preventive screening initiatives, broadening the market scope beyond just emergency situations. Consequently, manufacturers experience greater adoption rates, leading to heightened research investments. This dynamic creates a continuous cycle of growth, with the overall trend toward proactive health management further amplifying these developments.

Restraints in the Global Heart Attack Diagnostics Market

The requirement for significant capital investment in advanced diagnostic equipment presents a major financial challenge for numerous healthcare facilities, particularly those in resource-limited environments. The high costs associated with acquiring cutting-edge technologies deter smaller hospitals and clinics from adopting these innovations, leading them to rely on outdated and less accurate diagnostic methods. Additionally, budgetary limitations hinder the maintenance and upgrading of existing systems, which prolongs the timeline for adoption. As a result, market penetration remains inconsistent, and overall growth is constrained by economic factors. Fiscal pressures often compel institutions to focus on immediate clinical needs rather than prioritize essential long-term diagnostic improvements.

Market Trends of the Global Heart Attack Diagnostics Market

The Global Heart Attack Diagnostics market is experiencing a significant shift toward AI-driven imaging interpretation, as advanced algorithms are increasingly integrated into cardiac imaging systems. This innovation enables real-time analysis of ECG, echocardiography, and CT scans, dramatically reducing interpretation times and enhancing diagnostic reliability by minimizing inter-operator variability. Hospitals are actively adopting AI-enhanced platforms to streamline workflows and bolster clinician confidence in diagnoses. Collaborations between vendors and technology firms are becoming commonplace, facilitating the incorporation of sophisticated learning models into diagnostic tools. Consequently, these developments accelerate clinical decision-making and align with value-based care initiatives, ultimately benefiting patients and healthcare systems alike.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Heart Attack Diagnostics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Troponin (cTnI, cTnT) Tests
• CK-MB (Creatine Kinase-MB)
• Myoglobin Tests
• BNP/NT-proBNP
• ECG

Global Heart Attack Diagnostics Market Size by Platform & CAGR (2026-2033)

• Market Overview
• High-Sensitivity Assays
• Standard Assays
• POC Tests

Global Heart Attack Diagnostics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospital Emergency Departments
• ICU & Cardiac Care
• Ambulatory Clinics

Global Heart Attack Diagnostics Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Laboratory Distributors

Global Heart Attack Diagnostics Market Size & CAGR (2026-2033)

• North America (Test Type, Platform, End-User, Distribution)
  • US
  • Canada
• Europe (Test Type, Platform, End-User, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Platform, End-User, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Platform, End-User, Distribution)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Platform, End-User, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Abbott Laboratories (STAT Troponin)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Elecsys Troponin T)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter (Danaher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ortho Clinical Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quidel Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Response Biomedical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Critical Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tosoh Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Minicare (Philips)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Radiometer Medical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPTI Medical Systems
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Microvix
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenMark Diagnostics (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akers Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meso Scale Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boditech Med Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BTNX Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations